EXOSOMAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.
1 . An exosomal composition, comprising a therapeutic agent selected from a phytochemical agent, a chemotherapeutic agent, and a Stat3 inhibitor, the therapeutic agent being encapsulated by an exosome.
2 . The exosomal composition of claim 1 , where the therapeutic agent is a phytochemical agent selected from the group consisting of curcumin, resveratrol, baicalein, equol, fisetin, and quercetin.
3 . The exosomal composition of claim 2 , wherein the phytochemical agent is curcumin.
4 . The exosomal composition of claim 1 , wherein the therapeutic agent is a Stat3 inhibitor.
5 . The exosomal composition of claim 4 , wherein the Stat3 inhibitor is JSI-124.
6 . The exosomal composition of claim 1 , wherein the therapeutic agent is a chemotherapeutic agent.
7 . The exosomal composition of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, adriamycin, cisplatin, docetaxel, doxorubicin, and taxol.
8 . The exosomal composition of claim 1 , wherein the exosome is isolated from a cell.
9 . The exosomal composition of claim 8 , wherein the cell is a cancer cell.
10 . The exosomal composition of claim 9 , wherein the cancer cell is selected from a lymphoma cell, an adenocarcinoma cell, and a breast cancer cell.
11 . A pharmaceutical composition, comprising an exosomal composition according to claim 1 and a pharmaceutically-acceptable vehicle, carrier, or excipient.
12 . A method for treating an inflammatory disorder, comprising administering to a subject in need thereof an effective amount of an exosomal composition comprising a therapeutic agent selected from a phytochemical agent and a Stat3 inhibitor, the therapeutic agent being encapsulated by an exosome.
13 . The method of claim 12 , wherein the therapeutic agent is a phytochemical agent selected from the group consisting of curcumin, resveratrol, baicalein, equol, fisetin, and quercetin.
14 . The method of claim 13 , wherein the phytochemical agent is curcumin.
15 . The method of claim 12 , wherein the therapeutic agent is a Stat3 inhibitor.
16 . The method of claim 15 , wherein the Stat3 inhibitor is JSI-124.
17 . The method of claim 12 , wherein the inflammatory disorder is a brain-related inflammatory disorder.
18 . The method of claim 17 , wherein the exosomal composition is administered intranasally.
19 . The method of claim 12 , wherein the inflammatory disorder is an autoimmune disease.
20 . The method of claim 19 , wherein the autoimmune disorder is selected from the group consisting of lupus, rheumatoid arthritis, and autoimmune encephalomyelitis.
21 . The method of claim 12 , wherein administering the exosomal composition reduces an amount of an inflammatory cytokine in a subject.
22 . The method of claim 21 , wherein the inflammatory cytokine is selected from the group consisting of interleukin-1β, tumor necrosis factor-α, and interleukin-6.
23 . A method for treating a cancer, comprising administering to a subject in need thereof an effective amount of an exosomal composition comprising a therapeutic agent selected from a phytochemical agent, a chemotherapeutic agent, and a Stat3 inhibitor, the therapeutic agent being encapsulated by an exosome.
24 . The method of claim 23 , wherein the cancer is selected from the group consisting of skin cancer, head and neck cancer, colon cancer, breast cancer, brain cancer, and lung cancer.
25 . The method of claim 23 , wherein the cancer is a brain cancer.
26 . The method of claim 25 , wherein the brain cancer is a glioma.
27 . The method of claim 23 , where the therapeutic agent is a phytochemical agent selected from the group consisting of curcumin, resveratrol, baicalein, equol, fisetin, and quercetin.
28 . The method of claim 27 , wherein the phytochemical agent is curcumin.
29 . The method of claim 23 , wherein the therapeutic agent is a Stat3 inhibitor.
30 . The method of claim 29 , wherein the Stat3 inhibitor is JSI-124.
31 . The method of claim 23 , wherein the therapeutic agent is a chemotherapeutic agent.
32 . The method of claim 31 , wherein the chemotherapeutic agent is selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, adriamycin, cisplatin, docetaxel, doxorubicin, and taxol.
33 . The method of claim 23 , wherein the exosomal composition is administered intranasally, orally, or intratumorally.